Session #3: Targeted Therapies, Epigenetics, and Murine Models in JMML 10:45 Noon Organized by Rebecca Chan, M.D., Ph.D. – 10:45 11:00 Qing Li, University of Michigan – reprogramming in oncogenic N-RasG12D-induced pre-leukemic stem cell “Metabolic transformation” 11:00 11:15 Silvia Fluhr, University of Freiburg – changes accompany disordered hemoglobin regulation in JMML” “Epigenetic 11:15 11:30 Christopher Felix Krombholz, University of Freiburg – Reduces Leukemic Burden in a Xenograft Trial of Juvenile “5-Azacytidine Myelomonocytic Leukemia” 11:30 11:45 Bruce Gelb, Mount Sinai School of Medicine – JMML using Human iPSCs” “Modeling 11:45 noon Open Discussion – Lunch Buffet Noon 12:30 PM – Session #4: Update on Ongoing and Planned Clinical Trials 12:30 1:50 PM Organized by Rebecca Chan, M.D., Ph.D. – 12:30 12:50 Chris Dvorak, UC at San Francisco – Lessons Learned From a of Randomizing Transplant Conditioning “ASCT1221: Regimens” 12:50 1:10 Marry van den Heuvel-Eibrink & Charlotte Niemeyer – azacitidine for JMML and MDS in childhood: a retrospective analysis of “Low-dose the EWOG-MDS study group and ongoing prospective clinical and research studies in collaboration with EWOG-MDS and ITCC” 1:10 1:30 Elliot Stieglitz, UC at San Francisco – A Phase 2 Study of the MEK inhibitor Trametinib in Children with “ADVL1521: Relapsed or Refractory Juvenile Myelomonocytic Leukemia” Update of Roadmap 1:30 2 PM – Adjournment 2 PM
Session #3: Targeted Therapies, Epigenetics, and Murine Models in JMML 10:45 – Noon Organized by Rebecca Chan, M.D., Ph.D. 10:45 – 11:00 Qing Li, University of Michigan “Metabolic reprogramming in oncogenic N-RasG12D-induced pre-leukemic stem cell transformation” 11:00 – 11:15 Silvia Fluhr, University of Freiburg “Epigenetic changes accompany disordered hemoglobin regulation in JMML” 11:15 – 11:30 Christopher Felix Krombholz, University of Freiburg “5-Azacytidine Reduces Leukemic Burden in a Xenograft of Juvenile Myelomonocytic Leukemia” 11:30 – 11:45 Bruce Gelb, Mount Sinai School of Medicine “Modeling JMML using Human iPSCs” 11:45 – noon Open Discussion Lunch Buffet Noon – 12:30 PM Session #4: Update on Ongoing and Planned Clinical Trials 12:30 – 1:50 PM Organized by Rebecca Chan, M.D., Ph.D. 12:30 – 12:50 Chris Dvorak, UC at San Francisco “ASCT1221: Lessons Learned From a Trial of Randomizing Transplant Conditioning Regimens” 12:50 – 1:10 Marry van den Heuvel-Eibrink & Charlotte Niemeyer “Low-dose azacitidine for JMML and MDS in childhood: a retrospective analysis of the EWOG-MDS study group and ongoing prospective clinical and research studies in collaboration with EWOG-MDS and ITCC” 1:10 – 1:30 Elliot Stieglitz, UC at San Francisco “ADVL1521: A Phase 2 Study of the MEK inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia” Update of Roadmap 1:30 – 2 PM Adjournment 2 PM
JMML%20Working%20Group%20FINAL%20agenda.docx